Aptinyx Backs off on Study Results

Aptinyx Inc. (NASDAQ:APTX) had trouble gaining traction Tuesday on word of its treatment for dementia.

The clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has recommenced patient screening in a Phase 2 study of NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson’s disease and dementia with Lewy bodies.

The Phase 2 study is a randomized, double-blind, parallel-design, placebo-controlled study to evaluate the safety and potential cognitive benefits of NYX-458 in approximately 100 patients with mild cognitive impairment or mild dementia associated with Parkinson’s disease or prodromal or manifest dementia with Lewy bodies.

The study will evaluate daily oral dosing of NYX-458 30 mg compared to placebo over a 12-week period. The study will evaluate the overall safety and tolerability of NYX-458 in patients and the potential cognitive benefits of NYX-458 will be evaluated across multiple neurocognitive endpoints focused on attention, memory, and executive function.

Said CEO Norbert Riedel, “We are pleased to be moving forward in evaluating NYX-458 in patients suffering from cognitive impairment.

“Current therapies for these patients often do not deliver meaningful benefits and there is a great need for new therapeutic options. We believe the mechanism of NYX-458 is uniquely suited to address the cognitive deficits experienced by these patients and we look forward to building on the compelling preclinical data we have garnered with NYX-458 to date.”

APTX opened trading Tuesday down 8.5 cents, or 2.6%, to 3.135.

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire